Drug intelligence / Profile preview

VTx-005

Development stage: Unknown
Lead developer: VectorY Therapeutics
Modality: Gene Therapies, Antibody-Based Therapeutics

Overview

VTx-005 is an antibody-based drug developed by VectorY BV. It is described as a DNA encoding monoclonal antibody (mab) and AAV-based gene therapy. The specific mechanism of action, therapeutic targets, and indications have not been disclosed publicly. The drug is currently in the discovery phase of development with no clinical trial data or approved indications available yet. It appears to be part of VectorY BV's pipeline focused on neurodegenerative diseases but exact disease targets for VTx-005 are not specified.

Other names: VTx-005VTx005VTx 005

Beyond the preview

Go deeper on VTx-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VTx-005.

Explore the full profile